Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Showcases Unique MS Drug Candidate, Growth Strategy During Executive Podcast

Austin, Texas, United States, July 1st, 2026, FinanceWire

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.

• Quantum BioPharma executive co-chairman and co-founder Anthony Durkacz appeared as a guest on the BioMedWire Podcast.
• Durkacz outlined the company’s strategy for advancing Lucid-MS, the company’s lead drug candidate for multiple sclerosis.
• The Quantum BioPharma exec also provided an update on unbuzzd, the company’s innovative, clinically validated alcohol metabolism accelerator designed to help sober people up faster.

Executive thought leadership has become an increasingly important component of corporate communications, particularly in highly specialized industries such as biotechnology. Through podcasts, interviews and other educational forums, company leaders can explain complex technologies, discuss development strategies and provide context that is often difficult to capture in traditional press releases. That approach was recently on display when Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) executive co-chair and co-founder Anthony Durkacz appeared as a guest on the BioMedWire Podcast.

Quantum BioPharma is a biopharmaceutical company focused on developing treatments for neurodegenerative, metabolic and alcohol-misuse disorders, with Lucid-MS and its ownership in commercially product unbuzzd(TM). During the interview, Durkacz outlined the company’s strategy for…

Read More>>

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

Contact